but also have K + -channel blocking and -blocking effects. 11 Pilsicainide has pure and strong Na + -channel-blocking effects and is the drug most often used in Japan for clinical drug challenge tests, 12 therefore we used it in the present study to assess the influence of pilsicainide on the surface ECG not only in patients suspected of BS, but also in patients in whom Na + -channel blockers would be used.
Methods

Subjects
We prospectively studied 161 consecutive patients who had normal left ventricular function with no evidence of typical Brugada signs on their baseline ECG during hospitalization and who consented to a Na + -channel-blocker challenge test during the period from January 2002 to August 2005. There were 135 males and 26 females with a mean age of 53±15 years. The pilsicainide test was performed in symptomatic (n=95, 79 males, 52±16 years) and asymptomatic (n=66, 56 males, 54±14 years) patients. The symptomatic patients had a history of documented arrhythmias other than ventricular tachycardia (VT) or ventricular fibrillation (VF), or episodes related to brain ischemia such as syncope or fainting, but no documented arrhythmias at that time. In the present study, VT was defined as more than ventricular triplets. The asymptomatic patients were selected from a healthy population with documented ECG abnormalities suspected of being Brugada-type or Brugadalike, other than ones with the coved-type ST elevation or with arrhythmias such as ventricular premature contractions (VPCs) or atrial premature contractions diagnosed by yearly health check-ups (Table 1) .
Three types of repolarization pattern were recognized and defined as types 1, 2 and 3 according to the Heart Rhythm Society and the European Heart Rhythm Association. 4 We used these ECG criteria and excluded subjects exhibiting type 1 ECGs in the standard leads in the control state. We also excluded patients with VT (≥triplets), or a family history of BS or sudden unexpected death. All cases then underwent echocardiography with careful attention paid to any right ventricular (RV) enlargement and/or wall motion abnormalities and were also checked for conditions and agents that may lead to ST-segment elevation. 4 Therefore, patients with organic heart disease or other factors that may have influenced ST-segment elevation were excluded. All patients gave written informed consent to participate in the study, which was approved by the Institutional Clinical Research and Ethics Committee.
Na + -Channel-Blocker Challenge Test
We performed a Na + -channel-blocker challenge test using pilsicainide, a so-called pure Na + -channel blocker, in a room with a defibrillator and life support facilities. Pilsicainide was administrated intravenously at a speed of 0.1 mg·kg -1 ·min -1 over 10 min (total 1 mg/kg) with continuous ECG and non-invasive blood pressure monitoring. During drug administration, we monitored the ECG using the standard 12 leads, but after performing 96 tests, we began monitoring not only the standard right precordial leads V1-3, but also those recorded from 1 intercostal space (ICS) higher than the right precordial leads using the V4-6 electrodes, because in several cases we found marked ST elevation after the pilsicainide test in the higher right precordial leads only. Drug administration was immediately stopped when ST elevation (>0.5 mV), extensive QRS prolongation, unfavorable symptoms and/or frequent ventricular arrhythmias were observed. In this study, the test was considered positive if the abnormal coved-type ECG pattern (type 1 ECG) appeared in more than 1 right precordial lead.
Electrocardiography
Before and after the administration of pilsicainide, we recorded the standard 12-lead ECG (ECG-9322, Nihon Kohden Corp, Tokyo, Japan). The J wave amplitude (STJ; V) was analyzed by an organized computer algorithm (ECAPS 12C, Nihon Kohden). In the ECAPS 12C, the terminal point of the QRS (J point) was defined as the offset point of the QRS waveform determined from the averaged QRS waveforms from the 12 leads. After the drug test, we calculated the increase in the STJ (∆J) in each of the right precordial leads (V1-3). The maximum increase in the STJ (max∆J) was defined as the maximum value of ∆J of the 3 leads. Based on the ECG criteria, we defined it as either a "Brugada-type" type 1 ECG (coved type with an STJ ≥200 V), or "suspect Brugada-type" type 2/3 ECG (saddle-back type with an STJ ≥200 V), and these were reviewed by 2 independent cardiologists. The other ECGs without these criteria were defined as "normal", including Brugada "like" ECGs of either the coved or saddle-back type with an STJ <200 V and non-specific ST elevation with an STJ ≥200 V. As described in the primary consensus report, 4 an increase in the J wave amplitude of greater than 200 V was also considered a significant diagnostic value, and we assessed the prevalence of ST morphology and max∆J, with a cutoff point defined as 200 V in the high right precordial leads during Na + -channel blocker administration.
ECG From the High Right Precordium
To evaluate the ST-segment recorded from the high right precordium in all cases, we moved the 3 leads 1 or 2 ICS higher after making baseline recordings from the standard leads before and after pilsicainide. From all the ECGs recorded, including those from the higher placement of leads, we assessed the max∆J and ST morphology.
Statistical Analysis
Data are given as the mean ± SD. The ECG data were analyzed by paired t-test. The chi-square test for independence was used for comparisons of the prevalence of a type 1 ECG after giving pilsicainide in 2 groups divided by a cutoff point of 200 V for the max∆J. A value of p<0.05 was considered statistically significant.
Results
Pilsicainide Dose and Effect on J Wave Amplitude and QRS Width
In the 161 cases, the administration of pilsicainide was stopped in 21 when the ST junction in the right precordial leads became elevated by more than 0.5 mV and/or the number of VPCs and couplets increased. The mean dose was 0.97 mg/kg. Severe complications, such as VT or VF, did not occur.
Pilsicainide increased the STJ in each lead, and a significant increase in leads V2 and V3 recorded from both the standard and higher positions was especially noted. The QRS width was significantly prolonged in all patients ( Table 2) . Before After Including the recordings from the higher placement of the leads, in 10 cases a type 1 ECG before pilsicainide was documented, which in the baseline standard leads had been a type 2/3 ECG in 6 cases and normal ECG in 4 cases. After pilsicainide, 24 more cases had a documented type 1 ECG, which in the standard leads was a type 2/3 ECG in 5 cases and normal ECG in 19 cases (Fig 1) .
Distribution of the Maximum Increase in the STJ
In the standard ECG leads, a max∆J ≥200 V was observed in 29 cases (type 1 ECG in 23 cases, type 2/3 ECG in 2 cases, normal ECG in 4 cases) after pilsicainide (Fig 2) . In 5 of 6 cases that did not exhibit a type 1 ECG, a type 1 ECG could be detected when the right precordial leads were moved higher.
When the high right precordial leads were included, 16 more cases, which had a max∆J <200 V in the standard leads, had a max∆J ≥200 V. In 42 of 45 cases with a max∆J ≥200 V in which the higher leads were included, the ECG exhibited a type 1 ECG. In contrast, the max∆J in all the patients with a normal ECG after the pilsicainide test, even when recording from the higher leads, did not exceed 200 V. The prevalence of ST-segment morphology with a max∆J greater than and less than 200 V significantly differed for both recording methods (Fig 2) . Further, there were no normal ECGs with a max∆J ≥200 V in the analysis of the additional higher leads (Fig 2) . A representative case of a type 1 ECG in only the higher leads after pilsicainide is shown in Fig 3. Each value of the max∆J for each type of ST-segment morphology after pilsicainide, 
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including those for the additional higher leads, is plotted in Fig 4. Note that there were no patients with a max∆J ≥200 V in the normal ECGs after pilsicainide. In Fig 4  200 V max∆J represents the cutoff line and value that was used to divide the distribution of the normal ECGs from abnormal ECGs after pilsicainide.
Discussion
In the present study, we assessed the prevalence of a Brugada-type (type 1) ECG and the increase in the J wave amplitude in the right precordial leads, including higher placement of the leads, in order to evaluate the effects of pilsicainide on the ST-segment in the ECGs not exhibiting a type 1 ECG in the standard leads during the control state. We found that the prevalence of a type 1 ECG after pilsicainide was 19% and the prevalence of a max∆J ≥200 V after the test was 18% in the standard leads. By recording from the high right precordial leads, the prevalence of a type 1 ECG after pilsicainide increased by 9% (an additional 14 cases) and the prevalence of a max∆J ≥200 V after the test increased by 10% (an additional 16 cases) as compared with using only the standard leads. The majority of cases (23 of 29 in the standard leads and 42 of 45 in the high right precordial leads) with a max∆J ≥200 V exhibited a typical type 1 ECG. In contrast, cases that showed no obvious morphological ST-T changes (normal ECGs), even when the high right precordial leads were used in the analysis, had an increase in the amplitude of less than 200 V. To the best of our knowledge, there have been few reports describing evidence of positive criteria for the Na + challenge test. Our data supports the positive criteria of the pharmacologic test in the consensus report 4 and an increase in the J wave amplitude of greater than 200 V seems to have a meaningful significance for the diagnosis of a drug-induced BS compatible ECG.
Na + -Channel-Blocker Challenge Test Using Pilsicainide
It has been widely accepted that a shift in the balance of the current, which leads to the loss of the action potential dome in the RV outflow epicardium but not the endocardium, is the mechanism of ST elevation in the right precordial leads in BS. 13 With a reduction in the inward Na + currents (INa), the notch in the epicardial action potentials becomes deeper, producing a voltage gradient between the epicardium and endocardium. This voltage gradient produces ST elevation in the right precordial leads and induces lethal arrhythmias caused by phase 2 reentry. 13 Induction of VF during the drug challenge test or after the administration of Na + -channel blockers in patients with paroxysmal atrial fibrillation with typical ST-segment elevation has been described. 3, 14, 15 However, we carefully administered pilsicainide with continuous ECG monitoring and immediately discontinued administration when marked ST-segment elevation, excessive QRS prolongation or ventricular arrhythmias were observed. We completed the drug challenge test safely without any severe adverse events. 4, 9 Recently, an association of BS with atrial fibrillation, atrial vulnerability and supraventricular tachyarrhythmias has been reported. [16] [17] [18] Therefore, we performed the drug Representative case of type 1 ECG after pilsicainide recorded from the upper intercostal leads. A 29 year-old male, who had suffered from unexplained syncope, had ECGs recorded from the right precordial leads and 1 and 2 intercostal spaces (ICS) above leads V1-3. Before pilsicainide, non-specific ST elevation was observed in V2 and a type 2 ECG appeared in a recording from 1 ICS above V2 (arrow). After pilsicainide (1 mg/kg), type 1 ECGs were unmasked only in the high right precordial leads (arrowhead). The number shows the J wave amplitude ( V). challenge test not only in those who exhibited ECG abnormalities, but also in those who had some symptoms and/or various arrhythmias in order to diagnose drug-induced Brugada-type ECGs and/or to evaluate the safety of the drug. We used pilsicainide, which is a pure Na + -channel blocker and class Ic drug based on the Vaughan Williams classification. 19 Other class I anti-arrhythmic agents have ion channel blocking effects not only on the Na + channels but also on K + channels including the transient outward current (Ito), which mediates the spike-and-dome morphology of the epicardial action potential. 20, 21 By using a pure Na + channel blocker, changes in the ST-segment morphology, as viewed on the ECG, may directly reflect the drug's blocking effect on the Na + channel.
In regard to the assessment of the J wave amplitude, it is often difficult to determine the J point, especially with the Brugada sign, because of the obscurity of the end of the QRS and the beginning of the T wave. In order to avoid any error in the measurement using manual measurements, we performed a quantitative analysis using a computer algorithm.
Effects of Pilsicainide on ST-Segment Morphology and Elevation
In BS, some investigators have reported that the Brugada sign is more easily detected from the higher right precordium than in the usual standard ECG recording positions. [22] [23] [24] [25] However, Priori and Napolitano found that this maneuver led to an over-diagnosis of BS. 26 Further, the augmentation of ST-segment elevation by Na + -channel blockers may not be a specific response solely for BS. Peters et al reported that 16% of patients with RV cardiomyopathy respond with ST elevation to the Na + -channel challenge test 27 and Goda et al reported pilsicainide-induced coronary vasospasms in a patient with a Brugada-type ECG. 28 It also appears to be necessary to have a type 1 ECG after pilsicainide administration in order to differentiate a normal variant from BS.
There have been few reports about the prevalence of drug-induced Brugada-type ECGs in a relatively large group of patients with structurally normal hearts or in a healthy population. 8, 9 Hong et al 10 investigated the response to the ajmaline test in 4 large families with SCN5A mutations. The incidence of a positive test was high in the genetic carriers and low in the genetic non-carriers. Because we did not routinely perform genetic tests, it is unclear whether there was a relationship between the pilsicainide test and the genetic test.
Clinical Implications and Study Limitations
Because the observed drug-induced changes are surrogates for a genetic diagnosis of BS, the true meaning of a positive challenge is unknown and, therefore, of uncertain significance. However, because the present study showed that the ECG response to Na + -channel blockers exhibited a distinct difference in both the ST-T morphology and response of the J wave amplitude in the majority of cases, we believe that using the pilsicainide challenge test according to our method makes it possible to discriminate between a drug-induced Brugada-type ECG and normal variants.
It is still now an important issue as to whether or not the Na + channel challenge test can stratify the risk of cardiac events, so that we can give adequate recommendations or suggestions to our patients. In our study, the patients with an unmasked coved-type ST elevation are all alive. We still need a long-term follow-up of those patients to determine whether or not they will develop cardiac events.
Conclusion
The pilsicainide challenge test performed according to our protocol was safe and helpful for diagnosing drug-induced Brugada-type ECGs. Based on the response recorded in the right precordial leads, including the high right precordial leads, to pilsicainide, a max∆J ≥200 V was associated with a change mainly to a type 1 ECG. In this group there should be great concern for the possible risk of lethal arrhythmias.
